Advertisement
Advertisement
August 14, 2019
Cordis' Mynx Control Vascular Closure Device Gains CE Mark Approval
August 15, 2019—Cordis, a Cardinal Health company, announced that it has received European CE Mark approval for its Mynx Control vascular closure device (VCD). The company noted that VCDs have been proven to reduce time to hemostasis and ambulation in patients who have undergone diagnostic or interventional vascular procedures. In the United States, Cordis announced the launch the device in November 2018.
According to the company, the Mynx Control VCD integrates active extravascular sealing and full resorbability into a new delivery system that maximizes predictability, safety, and ease of use in closing 5- to 7-F femoral arterial access sites. The device's deployment system enables more predictable deployment and ease of use. Additionally, the system features automation of multiple procedural steps within the handle mechanism, a tension indicator that provides visual confirmation of device position for proper sealant deployment, and a new ergonomic handle design. The Mynx Control VCD is available in 5 F, as well as 6/7-F sizes.
Advertisement
Advertisement
